FDA Approves Guardant360 as Companion Diagnostic for BRAF-Mutant CRC
Guardant Health's liquid biopsy test wins CDx approval for encorafenib in BRAF V600E-mutant metastatic colorectal cancer, expanding the utility of blood-based genomic profiling across cancer types.
Apr 13, 2026 · 4 min read